At SyVento BioTech, we specialize in encapsulating your ideas and transforming them into cutting-edge pharmaceutical products using our advanced lipid-based drug delivery systems and LNP technology.

Lipid-based delivery systems can be carriers for a wide range of drug substances, including nucleic acids, small molecules (both hydrophilic and hydrophobic), peptides, and proteins.

The surface of liposomes and lipid nanoparticles can be modified with various molecules to facilitate targeting and enhance the therapeutic effect of the encapsulated drug.By encapsulating drugs, liposomes and LNPs can also facilitate targeted drug delivery to specific cells or tissues, enhancing their efficacy while minimizing adverse effects. Therefore, incorporating liposomes and LNPs into drug delivery systems is a promising strategy for optimizing drug therapy. They can also enable targeted drug delivery by attachment of antibodies (or their fragments), aptamers, peptides or any other ligands to their Surface that selectively bind to receptors on specific cells or tissues.

Liposomes and lipid nanoparticles are versatile drug delivery systems that offer several advantages over conventional drug formulations.
Liposomes are spherical vesicles composed of a lipid bilayer that can encapsulate both hydrophilic and hydrophobic drugs. Lipid nanoparticles, including solid lipid nanoparticles and nanostructured lipid carriers, are solid or semisolid particles composed of a lipid matrix that can also encapsulate a wide range of drugs. Liposomes and lipid nanoparticles (LNPs) play a crucial role in improving the pharmacokinetic and pharmacodynamic properties of drugs. These delivery systems protect drugs from degradation, enhance their solubility, and increase their bioavailability.


The history of lipid nanoparticle (LNP) research and development is characterized by continuous innovation and the pursuit of more effective drug delivery systems. Since the development of liposomes in 1965, researchers have been working on refining and expanding the applications of these lipid-based delivery systems. The 1978 development of liposome-mRNA formulations marked a pivotal moment in the intersection of RNA-based medicine and lipid-based delivery systems.

Over the years, various LNPs encapsulating different drugs have been approved by the FDA, and the use of LNP delivery systems for mRNA vaccines in 2020 showcased their potential to revolutionize medicine. SyVento BioTech builds on this legacy, actively shaping the landscape by developing cutting-edge lipid-based delivery systems that enable the safe and effective delivery of RNA-based therapeutics.

We offer the development of encapsulated drugs for all kinds of pharmaceutically active ingredients based on various lipid-based formulations such as:

  • Liposomes
  • Lipid nanoparticles (LNP) for gene therapies (both DNA & RNA)
  • Solid Lipid Nanoparticles (SLN)
  • Nanostructured lipid carriers (NLC)
  • Nanoemulsions
  • Self-emulsifying drug delivery system (SEDDS)

The developed formations are tested in accordance with the QbD (Quality by Design) and ICH guidelines.

As a biotechnology company, we offer contract development and production services that leverage our deep expertise and state-of-the-art facility.

Our team of experienced scientists and engineers work closely with our clients to develop customized solutions that meet their unique needs.

Partnering with SyVento BioTech gives you access to the latest industry developments and regulatory compliance, all while delivering innovative platform solutions that exceed your expectations.

Encapsulate your ideas with SyVento BioTech

and unlock the potential of lipid-based nanocarrier technology.

Advantages of lipid-based drug delivery systems

Increase in efficacy and therapeutic index (eg. Actinomycin D)

Act as Scaffold for additional agents

Possibility of several routes of administration (both inhalator and intravenous)

Protect encapsulated drug from metabolic digestion

Increases half life of drug

Biodegradable, bio-compatible & non-immunogenic

Can be made into variety of sizes

Reduced dosage

Reduces systemic toxicity of drug (eg. Taxol, Amphotericin B)


Can be targeted to specific tissues or cells

Can carry both lipid & water soluble drugs

Improved pharmacokinetic perfomance

Can be used as sustained drug release

It helps in reducing the exposure of sensitive tissues to toxic drugs (unmodified Liposomes gather in specific tissues like reticuloendothelial system)

Yadav D, Sandeep K, Pandey D, Dutta RK (2017) Liposomes for Drug Delivery. J Biotechnol Biomater 7: 276. DOI: 10.4172/2155-952X.1000276

Explore the benefits of our delivery platform:

Our team at SyVento BioTech possesses extensive qualifications and experience, enabling us to expertly develop lipid-based delivery systems, specifically focusing on LNP technology, which fosters essential outcomes like improved efficacy and enhanced support for diverse applications. Our LNP delivery systems:

  • help overcome the challenges of delivering fragile and easily degraded RNA molecules
  • improve the efficacy of mRNA based drugs are designed and optimized to achieve specific drug delivery goals
  • their modularity allows for precise control over the size surface charge, and composition

Lipid-based formulations are at the forefront of innovation in drug delivery systems. SyVento Biotech's platform solutions offer exciting possibilities for the future of drug products, with continued research and development in this area leading to new and innovative drug therapies that are more effective, safer, and better tolerated by patients.

A Comprehensive History of Lipid Nanoparticles for Drug Delivery Systems

Lipid nanoparticles have emerged as a versatile and effective drug delivery system, offering the potential to overcome the limits of conventional drug administration methods. Since their development, lipid nanoparticles have been used to enhance the bioavailability of drugs, reduce side effects, and improve therapeutic outcomes. The history of lipid nanoparticles for drug delivery systems can be traced back to the 1960s when British researcher Alec Bangham discovered liposomes. These spherical vesicles, composed of phospholipid bilayers, were initially developed as models for biological membranes. However, their potential for encapsulating and delivering hydrophilic and hydrophobic drugs soon became apparent. In the following decades, liposomes emerged as a promising drug delivery platform, with the first FDA-approved liposomal drug, Doxil, being introduced in 1995 for the treatment of AIDS-related Kaposi's sarcoma. Building on the success of liposomes, researchers sought to develop more stable and controlled-release drug delivery systems.

Exploring the Potential of Lipid Nanoparticle Technology for Targeted Drug Delivery

Lipid nanoparticles (LNPs) represent a groundbreaking advancement in drug delivery systems, primed to reshape the field of nucleic acid therapies. Although these therapies have demonstrated significant potential in addressing a wide array of diseases, their clinical implementation has faced challenges, such as poor bioavailability, rapid degradation, immune responses, and inefficient cellular uptake. LNPs offer a solution to these challenges by encapsulating nucleic acids in a protective environment, enhancing their stability and circulation time, and enabling targeted cellular delivery. The evolution of LNPs for nucleic acid delivery has progressed through several stages, starting with early liposome-based systems and advancing to sophisticated ionizable cationic lipid formulations. Ionizable cationic lipids have played a crucial role in enhancing the entrapment efficiency of LNPs, allowing for effective encapsulation and protection of nucleic acids while maintaining a near-neutral surface charge in circulation. This feature decreases rapid clearance and interactions with serum proteins, prolonging circulation half-life and improving bioavailability. Furthermore, LNPs can be tailored to target specific cells or tissues, reducing off-target effects and minimizing systemic toxicity. Research into lipid-based delivery systems began with the first in vitro demonstration of lipid-based transfection by Felgner et al. The introduction of ionizable cationic lipids and the optimization of loading strategies have enabled the efficient and scalable encapsulation of nucleic acids, addressing the challenges faced in their therapeutic application. LNPs have demonstrated significant promise in preclinical and clinical trials, delivering nucleic acid therapies to target cells with enhanced efficiency and reduced toxicity. One notable example is Patisiran, the first FDA-approved LNP-based RNAi therapy, which uses LNPs to deliver siRNA for the treatment of hereditary transthyretin-mediated amyloidosis. This success highlights the potential of LNPs in nucleic acid therapy and lays the groundwork for further development and application across a diverse range of diseases. In summary, LNPs provide a promising drug delivery system for nucleic acid therapies, overcoming several major barriers and amplifying the therapeutic potential of these treatments. Ongoing research and development in this field are anticipated to yield more effective and targeted nucleic acid-based therapies, revolutionizing the treatment of various diseases.

Enhancing mRNA Vaccine Stability and Efficacy through Lipid Nanoparticle Optimization

The swift development and distribution of mRNA vaccines, such as Pfizer/BioNTech and Moderna COVID-19 vaccines, have played a pivotal role in combating the SARS-CoV-2 pandemic. Utilizing lipid nanoparticle (LNP) technology has ensured efficient delivery and protection of mRNA from degradation. Despite its success, researchers continue to explore novel methods to further enhance the stability and efficacy of mRNA in LNP delivery systems. LNP-formulated mRNA vaccines comprise of various lipid components, including ionizable cationic lipids, which are crucial for effective mRNA delivery. To improve the stability and activity of mRNA vaccines, researchers are investigating the optimization of lipid compositions in LNPs. By fine-tuning the ratios of these lipid components, it is possible to minimize the formation of lipid-mRNA adducts, thus ensuring the mRNA remains translatable and maintains protein expression. In addition to optimizing lipid compositions, advanced formulation techniques are being explored to enhance the stability and efficacy of LNP-encapsulated mRNA. One such approach is the use of lipidoids, which are synthetic lipid-like molecules that can improve the encapsulation and release of mRNA. Lipidoids can potentially address some limitations of conventional lipid components, offering increased stability and more efficient delivery to target cells. The implementation of comprehensive analytical tools, such as mass spectrometry and cryogenic electron microscopy, provides crucial insights into the structure, stability, and behavior of LNPs. These tools aid in detecting impurities and understanding their impact on mRNA stability, ensuring the quality and safety of nucleic acid-based products. Strict quality control during manufacturing is also essential to limit impurities and guarantee the high quality of mRNA vaccines. As mRNA vaccines continue to gain prominence, there is a growing need to refine manufacturing processes and analytical methods, in order to ensure their stability and effectiveness. By optimizing lipid compositions, exploring advanced formulation techniques, and employing comprehensive analytical tools, scientists and manufacturers can enhance the safety and efficacy of mRNA vaccines. This progress will ultimately contribute to the development of more efficient and stable nucleic acid-based medicines that can tackle a broad spectrum of diseases and medical conditions.